SG10201701165TA - Angiopoietin-like 4 antibody and a method of its use in cancer treatment - Google Patents

Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Info

Publication number
SG10201701165TA
SG10201701165TA SG10201701165TA SG10201701165TA SG10201701165TA SG 10201701165T A SG10201701165T A SG 10201701165TA SG 10201701165T A SG10201701165T A SG 10201701165TA SG 10201701165T A SG10201701165T A SG 10201701165TA SG 10201701165T A SG10201701165T A SG 10201701165TA
Authority
SG
Singapore
Prior art keywords
angiopoietin
antibody
cancer treatment
cancer
treatment
Prior art date
Application number
SG10201701165TA
Inventor
Julien Lescar
Yee Hwa Wong
Wei Min Edmond Chua
Nguan Soon Andrew Tan
Han Chung Kelvin Chong
Ming Jie Tan
Royston-Luke Huang
Original Assignee
Univ Nanyang Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nanyang Tech filed Critical Univ Nanyang Tech
Publication of SG10201701165TA publication Critical patent/SG10201701165TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG10201701165TA 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment SG10201701165TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261682920P 2012-08-14 2012-08-14

Publications (1)

Publication Number Publication Date
SG10201701165TA true SG10201701165TA (en) 2017-03-30

Family

ID=50101350

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201408340SA SG11201408340SA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment
SG10201701165TA SG10201701165TA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201408340SA SG11201408340SA (en) 2012-08-14 2013-08-06 Angiopoietin-like 4 antibody and a method of its use in cancer treatment

Country Status (5)

Country Link
US (1) US20150210758A1 (en)
EP (1) EP2885319B1 (en)
CN (1) CN104768972B (en)
SG (2) SG11201408340SA (en)
WO (1) WO2014027959A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
TW201613977A (en) 2014-08-07 2016-04-16 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP4122957A1 (en) 2014-08-07 2023-01-25 Novartis AG Angiopoietin-like 4 antibodies and methods of use
CN115485297A (en) * 2020-04-27 2022-12-16 南洋理工大学 Humanized monoclonal antibodies against cANGPTL4

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US6989452B2 (en) 2001-05-31 2006-01-24 Medarex, Inc. Disulfide prodrugs and linkers and stabilizers useful therefor
CN102641503A (en) * 2004-07-20 2012-08-22 健泰科生物技术公司 Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2488640B1 (en) * 2009-10-14 2018-09-26 Nanyang Technological University Antiproliferative agent
WO2013022406A1 (en) * 2011-08-08 2013-02-14 Nanyang Technological University Angiopoietin-like 4 and its use in modulating cell leakiness

Also Published As

Publication number Publication date
EP2885319A4 (en) 2016-06-01
SG11201408340SA (en) 2015-01-29
EP2885319B1 (en) 2019-10-09
CN104768972B (en) 2019-12-06
EP2885319A1 (en) 2015-06-24
CN104768972A (en) 2015-07-08
WO2014027959A1 (en) 2014-02-20
US20150210758A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
HK1216251A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
HRP20182125T1 (en) Adenovirus expressing a fas-chimera and use thereof in cancer treatment methods
HK1221178A1 (en) Cabozantinib dosage form and use in the treatment of cancer
EP2814509A4 (en) Antibodies to integrin v 6 and use of same to treat cancer
HK1214274A1 (en) Lipopetides for use in treating liver diseases and cardiovascular diseases
PL3004112T3 (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
HK1211960A1 (en) Treating vascular disease and complications thereof
IL233875A0 (en) A composition and use thereof in the treatment of anal rhagades
SG10201701165TA (en) Angiopoietin-like 4 antibody and a method of its use in cancer treatment
PT2872176T (en) Carboranylporphyrins for use in the treatment of cancer
HK1203430A1 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
EP2744786A4 (en) Substituted 2-imidazolidinones and 2-imidazolones and their use in the treatment of cancer
GB201308753D0 (en) Compounds and their use in therapy
SG11201500186VA (en) Angiopoietin-like 4 and a method of its use in wound healing
EP2695604A4 (en) Spirulina-containing cosmetic composition and cosmetic treatment method
HK1209073A1 (en) Plod-2 stimulators and their use in the treatment of skin plod-2
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
GB201308217D0 (en) Compounds and their use in therapy